News
IMMP
1.965
-2.24%
-0.045
BRIEF-Immutep Ltd Says In Strong Cash Position Of $68.38 Million
Reuters · 4d ago
Immutep: A Worthy $2 Dart Throw
Seeking Alpha · 01/22 12:48
BRIEF-Immutep Achieves 50% Enrollment Milestone In Randomised Phase IIb TACTI-003 Trial
Reuters · 01/04 13:14
Immutep Tuesday, It Achieved 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Benzinga · 01/04 09:56
Sector Update: Healthcare Stocks Show Little Movement Friday
Sector Update: Healthcare Stocks Show Little Movement Friday
MT Newswires · 12/23/2022 16:26
Sector Update: Health Care Stocks Still Looking for Direction as Biotechs Weigh
Sector Update: Health Care Stocks Still Looking for Direction as Biotechs Weigh
MT Newswires · 12/23/2022 14:19
BRIEF-Immutep Announces Successful Meeting With The FDA On Eftilagimod Alpha Plus Chemotherapy For The Treatment Of Metastatic Breast Cancer
Reuters · 12/23/2022 13:02
Immutep Announced on Thursday, Successful Meeting With the FDA on Eftilagimod Alpha Plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Benzinga · 12/23/2022 10:11
Immutep Plans Q1 Launch of Phase 2 of Trial of Breast Cancer Tandem Treatment
Immutep Plans Q1 Launch of Phase 2 of Trial of Breast Cancer Tandem Treatment
MT Newswires · 12/23/2022 09:18
BRIEF-Immutep Says Successful Meeting With FDA On Eftilagimod Alpha Plus Chemotherapy
Reuters · 12/23/2022 05:24
BRIEF-Immutep Achieves Commercial Scale In Manufacturing Of Eftilagimod Alpha
Reuters · 12/08/2022 14:05
Immutep Successfully Achieves Commercial Scale In Manufacturing Of Eftilagimod Alpha
Benzinga · 12/08/2022 13:11
Immutep Announces GMP Manufacturing Process Developed For IMP761, A First-in-Class LAG-3 Agonist For Autoimmune Disease
Benzinga · 12/06/2022 13:13
BRIEF-Immutep Announces GMP Manufacturing Process Developed For IMP761
Reuters · 12/06/2022 13:12
'Immutep Enters Into Second Clinical Trial Collaboration Agreement With Merck KGaA, Darmstadt, Germany, And Pfizer For New Combination Study Of Its LAG-3 Candidate. Eftilagimod Alpha, And Avelumab To Treat Urothelial Cancer'
Benzinga · 11/28/2022 21:23
BRIEF-Immutep Receives Australian Research And Development Tax Incentive
Reuters · 11/14/2022 17:43
Immutep Receives A$986,286 Australian R&D Tax Rebate
Benzinga · 11/14/2022 00:56
Immutep Announces Clinical Results From Phase II Trial Utilizing Its First-in-class Soluble LAG-3 Protein, Eftilagimod Alpha, In 1st Line NSCLC At SITC 2022 Annual Meeting
Benzinga · 11/10/2022 16:12
BRIEF-Immutep Granted New Patents In Japan And South Korea
Reuters · 11/09/2022 15:44
Immutep gets patents in Japan, South Korea linked to immunotherapy eftilagimod
Seekingalpha · 11/09/2022 14:14
More
Webull provides a variety of real-time IMMP stock news. You can receive the latest news about Immutep through multiple platforms. This information may help you make smarter investment decisions.
About IMMP
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. Its other two product candidates include leramilimab (IMP701), an immunotherapy for solid tumors, blood cancer and breast cancer, and GSK‘781 (IMP731) an immunotherapy for autoimmune diseases. The Company’s subsidiaries include Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.